Vical and Astellas Pharma announced the initiation of a multinational Phase 3 registration trial of ASP0113, or TransVax, in approximately 500 hematopoietic cell transplant, or HCT, recipients. Vical and Astellas entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113, Vical's investigational therapeutic vaccine designed to control cytomegalovirus in transplant recipients. Astellas is conducting the trial, and Vical is providing development, regulatory and manufacturing support. The companies expect to begin a separate Phase 2 trial of ASP0113 in solid organ transplant recipients later this year.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- Astellas Pharma